B. Riley analysts have highlighted a biotech stock that they remain buyers of despite its second-quarter revenue miss, as upcoming ...

This is a premium only article. To continue reading this and other premium stock market news articles please sign-in or upgrade to StreetInsider.com Premium below (Free Trial) LEARN MORE